ClinicalTrials.gg
Not yet recruitingNCT06147232PLUTOUpdated Jan 27, 2025

Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia

A Phase 2 interventional study of Sotagliflozin and Placebo in Nephropathy, Diabetic Nephropathies and Diabetes Mellitus, Type 1, sponsored by Steno Diabetes Center Copenhagen. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.

Primary conditionDiabetic NephropathiesRegistry: Kidney DiseasesReclassifiedWhy we changed it
Registry
Kidney Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Nephropathies
Why
  1. The study's listed conditions name Diabetic Nephropathies, a narrower term within Kidney Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Steno Diabetes Center Copenhagen · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Diabetic Nephropathies with a site in Denmark — 6 open to participants now, 6 under way, none of them phase 3. Diabetic Nephropathies · Denmark.

Planned enrollment
17th of 36
69 · median 61
Started
2025
with 1 other
Phase 2
14 of 42
3 open now
Registered
39th of 42
by date
Lead sponsor
9 of 42
Steno Diabetes Center Copenhagen

Among the 42 studies in Diabetic Nephropathies with a site in Denmark, this one is the 17th largest by planned enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 in phase 2, and was the 39th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

6 of the 42 studies in Diabetic Nephropathies with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetic Nephropathies with a site in Denmark, or all of them as a file.
02

Study summary

Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes. People with type 1 diabetes also have increased risk of cardiovascular and kidney disease, and may benefit from SGLT-inhibition. The exact mechanism of how SGLT-inhibition benefits the kidneys are yet unknown. Change in renal hypoxia may be a factor.

Objective: The primary aim of this study is to assess the effects of 12 weeks SGLT-1 and 2 inhibition on renal oxygenation in persons with type 1 diabetes and chronic kidney disease.

Further aims are to study if renal oxygen consumption and response to SGLT-inhibition differs between people of African-Caribbean or Northern European decent.

Additionally effects on left ventricular ejection fraction, kidney function and biomarkers in blood and urine will be explored.

Method: 12 weeks treatment with oral sotagliflozin or matching placebo as intervention. Kidney oxygenation and perfusion parameters and left ventricular ejection fraction will be assessed by functional magnetic resonance imaging. Kidney function and biomarkers will be assessed according to local hospital laboratory guidelines.

Design: Randomized, double-blinded, placebo-controlled, cross over intervention study.

Study population: 69 persons with type 1 diabetes and diabetic kidney disease with albuminuria will be included, 39 at Steno Diabetes Center Copenhagen, 30 at King's College London.

Endpoints: Primary end-point: Change from 0 to 12 weeks in dynamic R2*-weighted signal after treatment with sotagliflozin compared to placebo. Secondary endpoints: Change from 0 to 12 weeks with sotagliflozin compared with placebo on renal perfusion, renal artery flow, renal oxygen consumption, renal parenchymal triglyceride fraction, renal fibrosis, left ventricular ejection fraction, urinary albumin-creatinin ratio, ketone bodies, erythropoietin, pro brain natriuretic peptide, and plasma- and urine inflammation- and fibrosis biomarkers as well as difference after 12 weeks treatment in glomerular filtration rate.

Timeframe: Inclusion of patients from february 2024. Last visit september 2025. Presentation spring 2026, publication fall 2026.

03

Conditions studied

  • Nephropathy
  • Diabetic Nephropathies
  • Diabetes Mellitus, Type 1
  • Albuminuria
  • Diabetic Complications Renal
  • Diabetic Complications Cardiovascular
  • Hypoxia
04

In context

Diabetic Nephropathies Reclassified

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

This study's planned enrollment of 69 is below the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.

Browse Diabetic Nephropathies studies →

Lead sponsor

Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.

Compared within Diabetic Nephropathies, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Persons ≥ 18 years of age with a diagnosis of type 1 diabetes (age at onset \<40 years; permanent insulin treatment initiated within 1 year of diagnosis)
  2. Albuminuria: UACR > 100 mg/g (in ≥2 out 3 morning spot urine collections prior to randomization)
  3. estimated (eGFR) ≥25 and \< 75 ml/min/1.73m2
  4. Participants must be on stable renin-angiotensin system blocking treatment 4 weeks before start of study drug and throughout study duration.
  5. Able to understand the written participant information and give

Exclusion criteria

Exclusion Criteria:

  1. Non-diabetic kidney disease indicated by medical history and/or laboratory findings.
  2. \< 25 ml/min/1.73m2, dialysis or kidney transplantation.
  3. Previous diabetic ketoacidosis, except at debut.
  4. Dysregulated diabetes ( > 85 mmol/mol)
  5. Decreased awareness or unawareness
  6. Pregnancy, lactating or with a wish of pregnancy within the next year
  7. Low carbohydrate diet
  8. Receiving therapy with an SGLT inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT inhibitor.
  9. (NYHA) class IV Congestive Heart Failure at the time of enrolment
  10. Myocardial infarction, unstable angina, stroke or within 12 weeks prior to enrolment
  11. The receipt of any product 90 days prior to this trial
  12. Unable to participate in study procedures
  13. Any disorder, except for conditions associated with type 1 diabetes, which in the Investigators opinion could interfere with the results of the trial
  14. Participation in another intervention study
  15. Exclusion criteria for MRI: known claustrophobia, known chronic lung disease, surgery within past 6 weeks or having foreign bodies of metal in the body (e.g. pacemaker, metal plates, metal screws)
  16. Recurrent urogenital infections.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    order: placebo/sotagliflozin

    first treatment period: 12 weeks placebo follow by: 6 weeks washout second treatment period: 12 weeks Sotagliflozin 200mg

    Drug: Sotagliflozin · Drug: Placebo

  • Experimental
    order: sotagliflozin/placebo

    first treatment period: 12 weeks Sotagliflozin 200mg follow by: 6 weeks washout second treatment period: 12 weeks placebo

    Drug: Sotagliflozin · Drug: Placebo

Interventions

  • Sodium-glucose-co-transporter 1 and 2 inhibitor

    Also known as: Inpefa (TM)

  • DrugPlacebo

    Placebo tablet

07

What researchers measure

Primary outcomes

  1. Change in dynamic R2*-weighted signal (BOLD) as an indirect measure of renal blood oxygenation

    difference between change from 0 to 12 weeks after treatment with sotagliflozin compared to treatment with placebo

    Time frame: 0 to 12 weeks in both treatment arms, last measure 30 weeks after randomization.

Secondary outcomes

  1. Change in renal perfusion (medullary and cortical)

    Measured with MRI by arterial spin labelling in mL/g/min

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization

  2. Change in renal artery flow

    Renal artery flow measured by using phase contrast (PC) MRI. It is measured in mL/min.

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization

  3. Change in renal oxygen consumption

    Renal oxygen consumption measured by MRI with T2-relaxation-under-spin-tagging.

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization

  4. Change in renal parenchymal triglyceride fraction

    Renal parenchymal triglyceride fraction is measured by MRI spectroscopy

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization

  5. Change in renal fibrosis

    Renal fibrosis is measured by MRI-derived apparent diffusion coefficient

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization

  6. Change in left ventricular ejection fraction

    Left ventricular ejection fraction is assessed by MRI

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization

  7. Change in albuminuria

    Urinary albumin-creatinine ratio (UACR) - morning void spot urine samples collected at home by participants.

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.

  8. Change in levels of ketone bodies

    Capillary blood ketones, possibly measured by continous ketone monitoring device

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.

  9. Change in plasma and urine inflammation- and fibrosis biomarkers

    Measured from blood and urine samples using a commercially available panel from the company Olink. Includes 92 biomarkers.

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.

  10. Change in endogenous erythropoietin

    Analysis on blood samples at regional hospital laboratory.

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.

  11. Change in pro brain natriuretic peptide

    Analysis on blood samples at regional hospital laboratory.

    Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.

  12. Difference in Kidney Function after 12 weeks treatment with sotagliflozin vs placebo

    Glomerular filtration rate. At Steno Diabetes Center Copenhagen this will be measured by plasma clearance of Tc-99m diethylene-triamine-pentaacetate.

    Time frame: From 12 to 30 weeks after randomization

Other outcomes

  1. Ethnicity

    if African-Caribbean ethnicity is associated with any of the above secondary outcomes or baseline differences in cardio-renal disease markers/imaging measures

    Time frame: From baseline to 30 weeks.

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for May 2027, 27 months later.

Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2023
First posted
Nov 27, 2023
StartEst.
Feb 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06147232
Responsible party
Sponsor
First posted
Nov 27, 2023
Start date
Feb 2025 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 27, 2025

Study contacts

Mette Brouw Iversen, MD
Contact
mette.brouw.iversen@regionh.dk
+4529267717
Peter Rossing, MD, DMSc
Contact
peter.rossing@regionh.dk
+4530913383

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotagliflozin

Start the discussion